ABIFINA
CONTATO
ASSOCIE-SE
LOGIN
  • Sobre
    • Quem somos
    • Código de Conduta Ética
    • Comitês
    • Estatuto Social
    • Estrutura organizacional
    • Galeria dos Presidentes
    • História
    • Segmentos da Química Fina
  • Prêmios
    • Prêmio Alcebíades de Mendonça Athayde
    • Prêmio Denis Barbosa
  • Associados
  • Notícias
    • ABIFINA na mídia
    • Associado em foco
    • Acontece na ABIFINA
    • Outras Notícias
  • Eventos
  • Produtos e serviços
    • ABIFINA Divulga
    • Clipping Diário de Notícias
    • Estatísticas
    • Centro de Monitoramento de Patentes
      • MPP Agro
      • MPP BIO
      • MPP Cannabis
      • MPP FDA
      • MPP FDA Biossimilares
      • MPP Saúde Animal
      • MPP SUS
    • Observatório de Ilegais
    • Panorama Regulatório Internacional
    • Propriedade Intelectual
      • Processo Administrativo de Nulidade (PAN)
      • Redação de Patentes
      • Relatórios de Patenteabilidade
      • Subsídios Técnicos
    • Resumo Semanal
  • Publicações
    • Revista FACTO
    • Todas as publicações
CONTATO

Repositório Covid-19

24/08/2022

Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks

Introduction

Since its emergence, there have been huge efforts to design vaccines against coronavirus disease 2019 (COVID-19) to inhibit its...

20/08/2022

Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019

Abstract

Background

19/08/2022

Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review

Abstract

Background: 

Remdesivir (RDV) is the main antiviral for the treatment of moderate to severe forms of Coronavirus disease 2019...

19/08/2022

Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION

Abstract

Background

More than 2.7 million hospitalizations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the...

18/08/2022

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Abstract

BACKGROUND

Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to...

18/08/2022

Endoplasmic reticulum secretory pathway: Potential target against SARS-CoV-2

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged throughout the world,...

18/08/2022

In silico Identification of Novel SARS-CoV-2 Main Protease and Nonstructural Protein 13 (nsp13) Inhibitors Through Consensus Docking and Free Binding Energy Calculations

Background: A new strain of a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently...

18/08/2022

Plant MicroRNA Potential in Targeting Sars-CoV-2 Genome Offering Efficient Antiviral MiRNA-Based Therapies

Background: In 2019, severe acute respiratory coronavirus II (or SARS-COV-2) emerged in Wuhan, China, rapidly becoming a global pandemic. Coronavirus...

18/08/2022

Endoplasmic reticulum secretory pathway: Potential target against SARS-CoV-2

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged throughout the world,...

17/08/2022

Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro

Abstract

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) helicase NSP13 plays a conserved role in the replication of coronaviruses and...

17/08/2022

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Abstract

Objectives

Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating...

17/08/2022

Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection

Abstract

SARS-CoV-2, the newly emerged virus of the Coronaviridae family is causing havoc worldwide. The novel coronavirus 2019 was first...

  • « anterior
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 38
  • 39
  • 40
  • 41
  • próxima »
  • Sobre
  • Associados
  • Notícias
  • Eventos
  • Estatísticas
  • Publicações
  • Contato
  • Política de Privacidade
Av. Churchill, 129 • Sala 1201 • Centro • Rio de Janeiro • RJ
+55 21 3125-1400 [email protected]

Todos os direitos reservados © 2025 - ABIFINA

Desenvolvido por Conceito Comunicação Integrada
Login
Esqueci a senha